# US 2017/0281591 A1 · Prodrug of green tea epigallocatechin-3-gallate (pro-egcg) for use in the treatment of endometriosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281591 A1
- Document ID: US20170281591A1
- Status: Published application
- Kind: A1
- Application number: 15/628,001
- Filed: 2017-06-20
- Published: 2017-10-05
- Earliest claimed: 2012-08-20
- Assignees: The Hong Kong Polytechnic University; The Chinese University of Hong Kong
- Applicants: The Hong Kong Polytechnic University; The Chinese University of Hong Kong
- Inventors: Tak-Hang Chan; Chi-Chiu Wang
- Web page: https://patentgrep.com/patent/US20170281591A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(−)-EGCG]. Use of Pro-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A composition comprising Pro-EGCG having the formula:
in an effective amount to treat endometriosis or a related indication in a subject in need thereof.

### Claim at position 3

8-18. (canceled)

### Claim 19 (depends on 7)

The composition according to claim 7 wherein the Pro-EGCG is in an effective amount to treat endometriosis.

### Claim 20 (depends on 19)

The composition according to claim 19 wherein the Pro-EGCG is in an effective amount to treat endometriosis, wherein said endometriosis is peritoneal or pelvic endometriosis.

### Claim 21 (depends on 7)

The composition according to claim 7 wherein the Pro-EGCG is in an effective amount to treat adenomyosis.

### Claim 22 (depends on 7)

The composition according to claim 7 wherein the Pro-EGCG is in an effective amount to treat endometriosis or a related indication in a subject in need thereof, wherein said Pro-EGCG is administered into the uterine cavity of the subject.

### Claim 23 (depends on 7)

The composition according to claim 7 wherein the Pro-EGCG is in an effective amount to treat endometriosis or a related indication in a subject in need thereof, wherein said Pro-EGCG is administered into the vagina of the subject.